13 April 2023: UCB, a global biopharmaceutical company, announced that The Lancet Neurology has published data from the Phase 3 MycarinG study evaluating the efficacy and safety of rozanolixizumab in adult patients with acetylcholine receptor autoantibody-positive (AChR-Ab+) or muscle-specific tyrosine kinase autoantibody-positive (MuSK-Ab+) generalised myasthenia gravis (gMG) and the Phase 3 RAISE study evaluating the…
Evobrutinib: Initiation of new patients paused in the US
News from Merck
Drug to lower brain pressure could treat blinding IIH headaches
March 13, 2023: Patients with ‘blinding’ headaches known as Idiopathic Intercranial Hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study, published in the journal Brain, reports on a phase two trial of a drug called exenatide, a GLP-1 receptor agonist, as a potential…
AI award for Queen Mary University of London and icometrix
Queen Mary and icometrix have together been awarded the prestigious AI Award in Health and Care by the National Institute for Health and Care Research (NIHR) 7th March 2023 The collaborative programme will investigate the impact of AI on the assessment of MRI and decision making for people with multiple sclerosis (MS). It is hoped…
Gamma-Frequency Sensory Stimulation decreases brain atrophy in patients with Alzheimer’s disease
On March 30th 2023 Cognito Therapeutics announced neuroimaging results evaluating the effects of the company’s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in participants with Alzheimer’s disease (AD). The results were presented at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, on March…
Can trichloroethylene (TCE) cause Parkinson’s disease (PD)?
In a paper published online on March 14th 2023 in the Journal of Parkinson’s Disease, researchers suggest that a common chemical, TCE, may be a key reason for the dramatic increase in Parkinson’s disease (PD). Lead investigator Ray Dorsey, MD, professor of neurology, University of Rochester, US has called PD “the world’s fastest-growing brain disease,” and said…
Phase 2 Trial of NLY01 in Parkinson’s Disease: Topline results
– This randomised, double-blind, placebo-controlled trial was designed to assess the safety, tolerability, and efficacy of NLY01 in subjects with early, untreated PD. – The primary endpoint, change from baseline in the sum of MDS-UPDRS Parts II and III after 36 weeks of NLY01 treatment, compared with placebo, did not reach statistical significance. – Age was identified as a significant…
Vestibular Rehabilitation in Concussion
Clinical Education in concussion at Southampton Football Club Emma Jewer, Concussion Service Lead at Hobbs Rehabilitation, recently delivered 2 workshops with practical and theory sessions to the medical teams from the youth, adult and women’s teams. This has led to requests for more practical training on baseline testing and embedding this into their existing rehab and…
Effects of median nerve stimulation on Tourette syndrome
Results of UK-wide double-blind sham-controlled clinical trial of the Neupulse device for suppressing tics in Tourette syndrome The trial was run by the University of Nottingham, conducted between 18th March 2022 and 5th of March 2023, sponsored by Nottingham University Hospitals NHS Trust. The aim was to evaluate the effectiveness of the Neupulse device in…
